“Receiving approval to apply the CE mark in Europe is critical to Lumendi’s overall global strategy to open markets around the world to continue improving endoscopic interventions and migrating many gastrointestinal surgeries to less invasive endolumenal procedures,” said Dr. Peter Johann, CEO of Lumendi Ltd. “To make the DiLumen EIP platform available across the EU, we are building a team to support our distributors in Europe in both marketing and clinical application.”
Originated in 1985, the CE mark is a symbol of free marketability in the European Economic Area. In July 2017, Lumendi received ISO 13485 certification, which is a harmonized medical device quality management system standard published by International Organization for Standardization (ISO) and required for distributing medical devices in many international markets, including the European Union.
To date, more than 400 procedures have been performed in the United States with the commercially available DiLumen EIP. Three clinical studies have been completed further demonstrating safety and cost effectiveness. The studies are expected to be published later this year.
The DiLumen Endolumenal Interventional Platform (EIP) is a non-sterile, single-use, close-fitting sleeve that fits securely over a standard endoscope to stabilize it in the large intestine and facilitates use of the endoscope for optical visualization, diagnosis, and treatment. DiLumen is the first device from the Endolumenal Interventional Platform based on Lumendi´s initiative to migrate many gastrointestinal surgeries to endolumenal procedures.
Lumendi Ltd. is headquartered in Buckinghamshire, United Kingdom. Lumendi is focused on developing, marketing and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions. Lumendi Ltd. holds a worldwide exclusive license from Cornell University on the DiLumen technology. Lumendi LLC is a wholly owned subsidiary based in Westport, Conn.